Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3-bromo-2-(bromomethyl)-6-chloropyridine is a pyridine derivative chemical compound characterized by the presence of a bromine atom at the 3rd and 2nd positions, a chloro group at the 6th position, and a bromomethyl group attached to the 2nd position. It is widely recognized for its role as a building block in the synthesis of pharmaceutical drugs and agrochemicals, particularly in the development of anti-cancer and anti-infective agents.

547756-20-7

Post Buying Request

547756-20-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

547756-20-7 Usage

Uses

Used in Pharmaceutical Industry:
3-bromo-2-(bromomethyl)-6-chloropyridine is used as a key intermediate in the synthesis of anti-cancer drugs and anti-infective agents. Its unique structure allows for the development of novel therapeutic agents with improved efficacy and selectivity against various diseases.
Used in Agrochemical Industry:
3-bromo-2-(bromomethyl)-6-chloropyridine is utilized in the development of agrochemicals and pesticides. Its versatile chemical properties enable the creation of effective compounds for pest control and crop protection, contributing to increased agricultural productivity and food security.
As a versatile chemical, 3-bromo-2-(bromomethyl)-6-chloropyridine has a broad range of applications in both the pharmaceutical and agricultural industries, making it an essential component in the advancement of innovative solutions for health and food production.

Check Digit Verification of cas no

The CAS Registry Mumber 547756-20-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,7,7,5 and 6 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 547756-20:
(8*5)+(7*4)+(6*7)+(5*7)+(4*5)+(3*6)+(2*2)+(1*0)=187
187 % 10 = 7
So 547756-20-7 is a valid CAS Registry Number.

547756-20-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-Bromo-2-(bromomethyl)-6-chloropyridine

1.2 Other means of identification

Product number -
Other names 3-Bromo-2-bromomethyl-6-chloropyridine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:547756-20-7 SDS

547756-20-7Downstream Products

547756-20-7Relevant articles and documents

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Huang, Ying,Zhang, Jeff,Yu, Zhengtian,Zhang, Hailong,Wang, Youzhen,Lingel, Andreas,Qi, Wei,Gu, Justin,Zhao, Kehao,Shultz, Michael D.,Wang, Long,Fu, Xingnian,Sun, Yongfeng,Zhang, Qiong,Jiang, Xiangqing,Zhang, Jiangwei,Zhang, Chunye,Li, Ling,Zeng, Jue,Feng, Lijian,Zhang, Chao,Liu, Yueqin,Zhang, Man,Zhang, Lijun,Zhao, Mengxi,Gao, Zhenting,Liu, Xianghui,Fang, Douglas,Guo, Haibing,Mi, Yuan,Gabriel, Tobias,Dillon, Michael P.,Atadja, Peter,Oyang, Counde

supporting information, p. 2215 - 2226 (2017/04/03)

Overexpression and somatic heterozygous mutations of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), are associated with several tumor types. EZH2 inhibitor, EPZ-6438 (tazemetostat), demonstrated clinical efficacy in patients with acceptable safety profile as monotherapy. EED, another subunit of PRC2 complex, is essential for its histone methyltransferase activity through direct binding to trimethylated lysine 27 on histone 3 (H3K27Me3). Herein we disclose the discovery of a first-in-class potent, selective, and orally bioavailable EED inhibitor compound 43 (EED226). Guided by X-ray crystallography, compound 43 was discovered by fragmentation and regrowth of compound 7, a PRC2 HTS hit that directly binds EED. The ensuing scaffold hopping followed by multiparameter optimization led to the discovery of 43. Compound 43 induces robust and sustained tumor regression in EZH2MUT preclinical DLBCL model. For the first time we demonstrate that specific and direct inhibition of EED can be effective as an anticancer strategy.

CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR

-

, (2012/05/19)

CCompounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substitiuted phenyl group or indanyl group.Formula (I)

PYRIDYL OXAZOLIDINONE CETP INHIBITOR

-

, (2011/04/14)

The compound of Formula I, including pharmaceutically acceptable salts, is a CETP inhibitor, and is useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula 1, R is H or Csub

CETP INHIBITORS

-

, (2008/06/13)

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

-

Page/Page column 37, (2008/06/13)

Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

Stereoselective synthesis of conformationally constrained tropane analogues: 6-Chloro-2,5-diazatetracyclo[8.5.0.02,13.0 4,9]pentadeca-4,6,8-triene-11-one and 6-chloro-2,7-diazatetracyclo- [8.5.0.02,13.04,9]pentadeca-4,6,8-triene-11-one

Cheng, Jie,Xu, Liang,Stevens, Edwin D.,Trudell, Mark L.,Izenwasser, Sari,Wade, Dean

, p. 569 - 574 (2007/10/03)

Two conformationally constrained tropane derivatives were prepared as rigid nicotinic acetylcholine receptor ligands. A palladium catalyzed intramolecular α-arylation reaction was employed to generate the tricyclic compounds in good yields from N-(bromo-chloropyridylmethyl)-8-azabicyclo[3.2.1]octan-3-ones.

P38 MAP kinase inhibitors. part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold

Natarajan, Swaminathan R.,Wisnoski, David D.,Singh, Suresh B.,Stelmach, John E.,O'Neill, Edward A.,Schwartz, Cheryl D.,Thompson, Chris M.,Fitzgerald, Catherine E.,O'Keefe, Stephen J.,Kumar, Sanjeev,Hop, Cornelis E. C. A.,Zaller, Dennis M.,Schmatz, Dennis M.,Doherty, James B.

, p. 273 - 276 (2014/12/12)

A new class of p38 antagonists based on 3,4-dihydropyrido[3,2,-d]pyrimidine scaffold has been developed. These inhibitors exhibit unprecedented selectivity towards p38 over other very closely related kinases. Compounds 25, 33, and 34 were identified as be

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 547756-20-7